5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Increases O
in O
serum O
transaminase O
levels O
and O
bilirubin O
were O
observed O
. O

Severe O
and O
fatal O
hepatotoxicity O
has O
occurred O
. O

Measure O
liver O
chemistries O
before O
the O
initiation O
of O
treatment O
and O
regularly O
during O
treatment O
. O

( O
5.1 O
) O
* O
Prolonged O
QT O
intervals O
and O
torsades O
de O
pointes O
have O
been O
observed O
. O

Use O
with O
caution O
in O
patients O
at O
higher O
risk O
of O
developing O
QT O
interval O
prolongation O
. O

Monitoring O
electrocardiograms O
and O
electrolytes O
should O
be O
considered O
. O

( O
5.2 O
) O
* O
Cardiac O
dysfunction O
such O
as O
congestive O
heart O
failure O
and O
decreased O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
have O
occurred O
. O

Monitor O
blood O
pressure O
and O
manage O
hypertension O
promptly O
. O

Baseline O
and O
periodic O
evaluation O
of O
LVEF O
is O
recommended O
in O
patients O
at O
risk O
of O
cardiac O
dysfunction O
. O

( O
5.3 O
) O
* O
Fatal O
hemorrhagic O
events O
have O
been O
reported O
. O

VOTRIENT O
has O
not O
been O
studied O
in O
patients O
who O
have O
a O
history O
of O
hemoptysis O
, O
cerebral O
, O
or O
clinically O
significant O
gastrointestinal O
hemorrhage O
in O
the O
past O
6 O
months O
and O
should O
not O
be O
used O
in O
those O
patients O
. O

( O
5.4 O
) O
* O
Arterial O
thromboembolic O
events O
have O
been O
observed O
and O
can O
be O
fatal O
. O

Use O
with O
caution O
in O
patients O
who O
are O
at O
increased O
risk O
for O
these O
events O
. O

( O
5.5 O
) O
* O
Venous O
thromboembolic O
events O
( O
VTE O
) O
have O
been O
observed O
, O
including O
fatal O
pulmonary O
emboli O
( O
PE O
) O
. O

Monitor O
for O
signs O
and O
symptoms O
of O
VTE O
and O
PE O
. O

( O
5.6 O
) O
* O
Thrombotic O
microangiopathy O
( O
TMA O
) O
, O
including O
thrombotic O
thrombocytopenic O
purpura O
( O
TTP O
) O
and O
hemolytic O
uremic O
syndrome O
( O
HUS O
) O
has O
been O
observed O
. O

Permanently O
discontinue O
VOTRIENT O
if O
TMA O
occurs O
. O

( O
5.7 O
) O
* O
Gastrointestinal O
perforation O
or O
fistula O
has O
occurred O
. O

Fatal O
perforation O
events O
have O
occurred O
. O

Use O
with O
caution O
in O
patients O
at O
risk O
for O
gastrointestinal O
perforation O
or O
fistula O
. O

( O
5.8 O
) O
* O
Interstitial O
lung O
disease O
( O
ILD O
) O
/pneumonitis O
have O
been O
observed O
and O
can O
be O
fatal O
. O

Discontinue O
VOTRIENT O
in O
patients O
developing O
ILD O
or O
pneumonitis O
. O

( O
5.9 O
) O
* O
Reversible O
Posterior O
Leukoencephalopathy O
Syndrome O
( O
RPLS O
) O
has O
been O
observed O
and O
can O
be O
fatal O
. O

Permanently O
discontinue O
VOTRIENT O
in O
patients O
developing O
RPLS O
. O

( O
5.10 O
) O
* O
Hypertension O
including O
hypertensive O
crisis O
has O
been O
observed O
. O

Blood O
pressure O
should O
be O
well O
controlled O
prior O
to O
initiating O
VOTRIENT O
. O

Monitor O
blood O
pressure O
within O
one O
week O
after O
starting O
VOTRIENT O
and O
frequently O
thereafter O
. O

( O
5.11 O
) O
* O
Interruption O
of O
therapy O
with O
VOTRIENT O
is O
recommended O
in O
patients O
undergoing O
surgical O
procedures O
. O

( O
5.12 O
) O
* O
Hypothyroidism O
may O
occur O
. O

Monitoring O
of O
thyroid O
function O
tests O
is O
recommended O
. O

( O
5.13 O
) O
* O
Proteinuria O
: O
Monitor O
urine O
protein O
. O

Interrupt O
treatment O
for O
24-hour O
urine O
protein O
> O
=3 O
grams O
and O
discontinue O
for O
repeat O
episodes O
despite O
dose O
reductions O
. O

( O
5.14 O
) O
* O
Infection O
: O
Serious O
infections O
( O
with O
or O
without O
neutropenia O
) O
, O
some O
with O
fatal O
outcome O
, O
have O
been O
reported O
. O

Monitor O
for O
signs O
and O
symptoms O
and O
treat O
active O
infection O
promptly O
. O

Interrupt O
or O
discontinue O
VOTRIENT O
. O

( O
5.15 O
) O
* O
Animal O
studies O
have O
demonstrated O
VOTRIENT O
can O
severely O
affect O
organ O
growth O
and O
maturation O
during O
early O
post-natal O
development O
. O

The O
safety O
and O
effectiveness O
in O
pediatric O
patients O
have O
not O
been O
established O
. O

( O
5.17 O
) O
* O
VOTRIENT O
can O
cause O
fetal O
harm O
when O
administered O
to O
a O
pregnant O
woman O
. O

Women O
of O
childbearing O
potential O
should O
be O
advised O
of O
the O
potential O
hazard O
to O
the O
fetus O
and O
to O
avoid O
becoming O
pregnant O
while O
taking O
VOTRIENT O
. O

( O
5.18 O
, O
8.1 O
) O
5.1 O
Hepatic O
Toxicity O
and O
Hepatic O
Impairment O
In O
clinical O
trials O
with O
VOTRIENT O
, O
hepatotoxicity B-OSE_Labeled_AE
, O
manifested O
as O
increases B-OSE_Labeled_AE
in O
serum O
transaminases O
( O
ALT O
, O
AST I-OSE_Labeled_AE
) O
and O
bilirubin O
, O
was O
observed O
. O

This O
hepatotoxicity B-OSE_Labeled_AE
can O
be O
severe O
and O
fatal B-NonOSE_AE
. O

Patients O
older O
than O
65 O
years O
are O
at O
greater O
risk O
for O
hepatotoxicity B-NonOSE_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
] O
. O

Transaminase B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
occur O
early O
in O
the O
course O
of O
treatment O
( O
92.5 O
% O
of O
all O
transaminase B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
of O
any O
grade O
occurred O
in O
the O
first O
18 O
weeks O
) O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

In O
the O
randomized O
RCC B-Not_AE_Candidate
trial O
, O
ALT B-OSE_Labeled_AE
> I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
X I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
was O
reported O
in O
18 O
% O
and O
3 O
% O
of O
the O
groups O
receiving O
VOTRIENT O
and O
placebo O
, O
respectively O
. O

ALT B-OSE_Labeled_AE
> I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
X I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
was O
reported O
in O
4 O
% O
of O
patients O
who O
received O
VOTRIENT O
and O
in O
< O
1 O
% O
of O
patients O
who O
received O
placebo O
. O

Concurrent O
elevation B-OSE_Labeled_AE
in O
ALT I-OSE_Labeled_AE
> O
3 O
X O
ULN O
and O
bilirubin B-OSE_Labeled_AE
> I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
X I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
in O
the O
absence O
of O
significant O
alkaline B-NonOSE_AE
phosphatase I-NonOSE_AE
> I-NonOSE_AE
3 I-NonOSE_AE
X I-NonOSE_AE
ULN I-NonOSE_AE
occurred O
in O
2 O
% O
( O
5/290 O
) O
of O
patients O
on O
VOTRIENT O
and O
1 O
% O
( O
2/145 O
) O
on O
placebo O
. O

In O
the O
randomized O
STS B-Not_AE_Candidate
trial O
, O
ALT B-OSE_Labeled_AE
> I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
X I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
was O
reported O
in O
18 O
% O
and O
5 O
% O
of O
the O
groups O
receiving O
VOTRIENT O
and O
placebo O
, O
respectively O
. O

ALT B-OSE_Labeled_AE
> I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
X I-OSE_Labeled_AE
ULN I-OSE_Labeled_AE
was O
reported O
in O
5 O
% O
and O
2 O
% O
of O
the O
groups O
receiving O
VOTRIENT O
and O
placebo O
, O
respectively O
. O

Concurrent O
elevation B-OSE_Labeled_AE
in O
ALT I-OSE_Labeled_AE
> O
3 O
X O
ULN O
and O
bilirubin O
> O
2 O
X O
ULN O
in O
the O
absence O
of O
significant O
alkaline B-NonOSE_AE
phosphatase I-NonOSE_AE
> I-NonOSE_AE
3 I-NonOSE_AE
X I-NonOSE_AE
ULN I-NonOSE_AE
occurred O
in O
2 O
% O
( O
4/240 O
) O
of O
patients O
on O
VOTRIENT O
and O
< O
1 O
% O
( O
1/123 O
) O
on O
placebo O
. O

Two-tenths O
percent O
of O
the O
patients O
( O
2/977 O
) O
from O
trials O
that O
supported O
the O
RCC B-Not_AE_Candidate
indication O
died B-NonOSE_AE
with O
disease B-NonOSE_AE
progression I-NonOSE_AE
and O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
and O
0.4 O
% O
of O
patients O
( O
1/240 O
) O
in O
the O
randomized O
STS O
trial O
died B-NonOSE_AE
of O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
. O

* O
Monitor O
serum O
liver O
tests O
before O
initiation O
of O
treatment O
with O
VOTRIENT O
and O
at O
Weeks O
3 O
, O
5 O
, O
7 O
, O
and O
9 O
. O

Thereafter O
, O
monitor O
at O
Month O
3 O
and O
at O
Month O
4 O
, O
and O
as O
clinically O
indicated O
. O

Periodic O
monitoring O
should O
then O
continue O
after O
Month O
4 O
. O

* O
Patients O
with O
isolated O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
between I-NonOSE_AE
3 I-NonOSE_AE
X I-NonOSE_AE
ULN I-NonOSE_AE
and O
8 O
X O
ULN O
may O
be O
continued O
on O
VOTRIENT O
with O
weekly O
monitoring O
of O
liver O
function O
until O
ALT O
returns O
to O
Grade O
1 O
or O
baseline O
. O

* O
Patients O
with O
isolated O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
of O
> O
8 O
X O
ULN O
should O
have O
VOTRIENT O
interrupted O
until O
they O
return O
to O
Grade O
1 O
or O
baseline O
. O

If O
the O
potential O
benefit O
for O
reinitiating O
treatment O
with O
VOTRIENT O
is O
considered O
to O
outweigh O
the O
risk O
for O
hepatotoxicity B-NonOSE_AE
, O
then O
reintroduce O
VOTRIENT O
at O
a O
reduced O
dose O
of O
no O
more O
than O
400 O
mg O
once O
daily O
and O
measure O
serum O
liver O
tests O
weekly O
for O
8 O
weeks O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

Following O
reintroduction O
of O
VOTRIENT O
, O
if O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
> O
3 O
X O
ULN O
recur O
, O
then O
VOTRIENT O
should O
be O
permanently O
discontinued O
. O

* O
If O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
> O
3 O
X O
ULN O
occur O
concurrently O
with O
bilirubin B-NonOSE_AE
elevations I-NonOSE_AE
> O
2 O
X O
ULN O
, O
VOTRIENT O
should O
be O
permanently O
discontinued O
. O

Patients O
should O
be O
monitored O
until O
resolution O
. O

VOTRIENT O
is O
a O
uridine O
diphosphate O
( O
UDP O
) O
-glucuronosyl O
transferase O
1A1 O
( O
UGT1A1 O
) O
inhibitor O
. O

Mild O
, O
indirect O
( O
unconjugated B-OSE_Labeled_AE
) I-OSE_Labeled_AE
hyperbilirubinemia I-OSE_Labeled_AE
may O
occur O
in O
patients O
with O
Gilbert B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
[ O
see O
Clinical O
Pharmacology O
( O
12.5 O
) O
] O
. O

Patients O
with O
only O
a O
mild O
indirect B-NonOSE_AE
hyperbilirubinemia I-NonOSE_AE
, O
known O
Gilbert B-NonOSE_AE
' I-NonOSE_AE
s I-NonOSE_AE
syndrome I-NonOSE_AE
, O
and O
elevation B-NonOSE_AE
in I-NonOSE_AE
ALT I-NonOSE_AE
> O
3 O
X O
ULN O
should O
be O
managed O
as O
per O
the O
recommendations O
outlined O
for O
isolated O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
. O

Concomitant O
use O
of O
VOTRIENT O
and O
simvastatin O
increases O
the O
risk O
of O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
and O
should O
be O
undertaken O
with O
caution O
and O
close O
monitoring O
[ O
see O
Drug O
Interactions O
( O
7.4 O
) O
] O
. O

Insufficient O
data O
are O
available O
to O
assess O
the O
risk O
of O
concomitant O
administration O
of O
alternative O
statins O
and O
VOTRIENT O
. O

In O
patients O
with O
pre-existing O
moderate O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
the O
starting O
dose O
of O
VOTRIENT O
should O
be O
reduced O
or O
alternatives O
to O
VOTRIENT O
should O
be O
considered O
. O

Treatment O
with O
VOTRIENT O
is O
not O
recommended O
in O
patients O
with O
pre-existing O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
defined O
as O
total O
bilirubin B-Not_AE_Candidate
> I-Not_AE_Candidate
3 I-Not_AE_Candidate
X I-Not_AE_Candidate
ULN I-Not_AE_Candidate
with O
any O
level O
of O
ALT O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
, O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

5.2 O
QT O
Prolongation O
and O
Torsades O
de O
Pointes O
In O
the O
RCC B-Not_AE_Candidate
trials O
of O
VOTRIENT O
, O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
( O
> O
=500 O
msec O
) O
was O
identified O
on O
routine O
electrocardiogram O
monitoring O
in O
2 O
% O
( O
11/558 O
) O
of O
patients O
. O

Torsades B-OSE_Labeled_AE
de I-OSE_Labeled_AE
pointes I-OSE_Labeled_AE
occurred O
in O
< O
1 O
% O
( O
2/977 O
) O
of O
patients O
who O
received O
VOTRIENT O
in O
the O
monotherapy O
trials O
. O

In O
the O
randomized O
RCC B-Not_AE_Candidate
and O
STS B-Not_AE_Candidate
trials O
, O
1 O
% O
( O
3/290 O
) O
of O
patients O
and O
0.4 O
% O
( O
1/240 O
) O
of O
patients O
, O
respectively O
, O
who O
received O
VOTRIENT O
had O
post-baseline O
values O
between O
500 O
to O
549 O
msec O
. O

Post-baseline O
QT O
data O
were O
only O
collected O
in O
the O
STS B-Not_AE_Candidate
trial O
if O
ECG B-NonOSE_AE
abnormalities I-NonOSE_AE
were O
reported O
as O
an O
adverse O
reaction O
. O

None O
of O
the O
268 O
patients O
who O
received O
placebo O
on O
the O
two O
trials O
had O
post-baseline O
QTc B-NonOSE_AE
values I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
msec I-NonOSE_AE
. O

VOTRIENT O
should O
be O
used O
with O
caution O
in O
patients O
with O
a O
history O
of O
QT B-Not_AE_Candidate
interval I-Not_AE_Candidate
prolongation I-Not_AE_Candidate
, O
in O
patients O
taking O
antiarrhythmics O
or O
other O
medications O
that O
may O
prolong B-NonOSE_AE
QT I-NonOSE_AE
interval I-NonOSE_AE
, O
and O
those O
with O
relevant O
pre B-Not_AE_Candidate
- I-Not_AE_Candidate
existing I-Not_AE_Candidate
cardiac O
disease I-Not_AE_Candidate
. O

When O
using O
VOTRIENT O
, O
baseline O
and O
periodic O
monitoring O
of O
electrocardiograms O
and O
maintenance O
of O
electrolytes O
( O
e.g. O
, O
calcium O
, O
magnesium O
, O
potassium O
) O
within O
the O
normal O
range O
should O
be O
performed O
. O

5.3 O
Cardiac O
Dysfunction O
In O
clinical O
trials O
with O
VOTRIENT O
, O
events O
of O
cardiac B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
such O
as O
decreased B-OSE_Labeled_AE
left I-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
ejection I-OSE_Labeled_AE
fraction I-OSE_Labeled_AE
( O
LVEF O
) O
and O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
have O
occurred O
. O

In O
the O
overall O
safety O
population O
for O
RCC B-Not_AE_Candidate
( O
N O
= O
586 O
) O
, O
cardiac B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
was O
observed O
in O
0.6 O
% O
( O
4/586 O
) O
of O
patients O
without O
routine O
on-study O
LVEF O
monitoring O
. O

In O
a O
randomized O
RCC B-Not_AE_Candidate
trial O
of O
VOTRIENT O
compared O
with O
sunitinib O
, O
myocardial B-NonOSE_AE
dysfunction I-NonOSE_AE
was O
defined O
as O
symptoms O
of O
cardiac B-NonOSE_AE
dysfunction I-NonOSE_AE
or O
> O
=15 O
% O
absolute O
decline B-NonOSE_AE
in I-NonOSE_AE
LVEF I-NonOSE_AE
compared O
with O
baseline O
or O
a O
decline B-NonOSE_AE
in I-NonOSE_AE
LVEF I-NonOSE_AE
of I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
% I-NonOSE_AE
compared O
with O
baseline O
that O
is O
also O
below O
the O
lower O
limit O
of O
normal O
. O

In O
patients O
who O
had O
baseline O
and O
follow O
up O
LVEF O
measurements O
, O
myocardial B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
occurred O
in O
13 O
% O
( O
47/362 O
) O
of O
patients O
on O
VOTRIENT O
compared O
with O
11 O
% O
( O
42/369 O
) O
of O
patients O
on O
sunitinib O
. O

Congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
occurred O
in O
0.5 O
% O
of O
patients O
on O
each O
arm O
. O

In O
the O
randomized O
STS B-Not_AE_Candidate
trial O
, O
myocardial B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
occurred O
in O
11 O
% O
( O
16/142 O
) O
of O
patients O
on O
VOTRIENT O
compared O
with O
5 O
% O
( O
2/40 O
) O
of O
patients O
on O
placebo O
. O

One O
percent O
( O
3/240 O
) O
of O
patients O
on O
VOTRIENT O
in O
the O
STS B-Not_AE_Candidate
trial O
had O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
which O
did O
not O
resolve O
in O
one O
patient O
. O

Fourteen O
of O
the O
16 O
patients O
with O
myocardial B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
treated O
with O
VOTRIENT O
in O
the O
STS B-Not_AE_Candidate
trial O
had O
concurrent O
hypertension B-Not_AE_Candidate
which O
may O
have O
exacerbated O
cardiac B-NonOSE_AE
dysfunction I-NonOSE_AE
in O
patients O
at O
risk O
( O
e.g. O
, O
those O
with O
prior O
anthracycline O
therapy O
) O
possibly O
by O
increasing B-NonOSE_AE
cardiac I-NonOSE_AE
afterload I-NonOSE_AE
. O

Blood O
pressure O
should O
be O
monitored O
and O
managed O
promptly O
using O
a O
combination O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
therapy I-NonOSE_AE
and O
dose O
modification O
of O
VOTRIENT O
( O
interruption O
and O
re-initiation O
at O
a O
reduced O
dose O
based O
on O
clinical O
judgment O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
. O

Patients O
should O
be O
carefully O
monitored O
for O
clinical O
signs O
or O
symptoms O
of O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
. O

Baseline O
and O
periodic O
evaluation O
of O
LVEF O
is O
recommended O
in O
patients O
at O
risk O
of O
cardiac B-NonOSE_AE
dysfunction I-NonOSE_AE
including O
previous O
anthracycline O
exposure O
. O

5.4 O
Hemorrhagic O
Events O
Fatal O
hemorrhage B-OSE_Labeled_AE
occurred O
in O
0.9 O
% O
( O
5/586 O
) O
in O
the O
RCC B-Not_AE_Candidate
trials O
; O
there O
were O
no O
reports O
of O
fatal B-NonOSE_AE
hemorrhage B-NonOSE_AE
in O
the O
STS B-Not_AE_Candidate
trials O
. O

In O
the O
randomized O
RCC B-Not_AE_Candidate
trial O
, O
13 O
% O
( O
37/290 O
) O
of O
patients O
treated O
with O
VOTRIENT O
and O
5 O
% O
( O
7/145 O
) O
of O
patients O
on O
placebo O
experienced O
at O
least O
1 O
hemorrhagic B-OSE_Labeled_AE
event I-OSE_Labeled_AE
. O

The O
most O
common O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
the O
patients O
treated O
with O
VOTRIENT O
were O
hematuria B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
epistaxis B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
hemoptysis B-OSE_Labeled_AE
( O
2 O
% O
) O
, O
and O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
1 O
% O
) O
. O

Nine O
of O
37 O
patients O
treated O
with O
VOTRIENT O
who O
had O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
experienced O
serious O
events O
including O
pulmonary B-OSE_Labeled_AE
, O
gastrointestinal O
, O
and O
genitourinary O
hemorrhage I-OSE_Labeled_AE
. O

One O
percent O
( O
4/290 O
) O
of O
patients O
treated O
with O
VOTRIENT O
died B-NonOSE_AE
from O
hemorrhage B-OSE_Labeled_AE
compared O
with O
no O
( O
0/145 O
) O
patients O
on O
placebo O
. O

In O
the O
overall O
safety O
population O
in O
RCC B-Not_AE_Candidate
( O
N O
= O
586 O
) O
, O
cerebral B-OSE_Labeled_AE
/intracranial O
hemorrhage I-OSE_Labeled_AE
was O
observed O
in O
< O
1 O
% O
( O
2/586 O
) O
of O
patients O
treated O
with O
VOTRIENT O
. O

In O
the O
randomized O
STS B-Not_AE_Candidate
trial O
, O
22 O
% O
( O
53/240 O
) O
of O
patients O
treated O
with O
VOTRIENT O
compared O
with O
8 O
% O
( O
10/123 O
) O
treated O
with O
placebo O
experienced O
at O
least O
1 O
hemorrhagic B-OSE_Labeled_AE
event I-OSE_Labeled_AE
. O

The O
most O
common O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
epistaxis B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
mouth B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
and O
anal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
2 O
% O
) O
. O

Grade O
4 O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
the O
STS B-Not_AE_Candidate
population O
occurred O
in O
1 O
% O
( O
3/240 O
) O
of O
patients O
and O
included O
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
subarachnoid B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
and O
peritoneal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
. O

VOTRIENT O
has O
not O
been O
studied O
in O
patients O
who O
have O
a O
history O
of O
hemoptysis B-Not_AE_Candidate
, O
cerebral B-Not_AE_Candidate
hemorrhage I-Not_AE_Candidate
, O
or O
clinically O
significant O
gastrointestinal B-Not_AE_Candidate
hemorrhage I-Not_AE_Candidate
in O
the O
past O
6 O
months O
and O
should O
not O
be O
used O
in O
those O
patients O
. O

5.5 O
Arterial O
Thromboembolic O
Events O
Fatal O
arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
observed O
in O
0.3 O
% O
( O
2/586 O
) O
of O
patients O
in O
the O
RCC B-Not_AE_Candidate
trials O
and O
in O
no O
patients O
in O
the O
STS B-Not_AE_Candidate
trials O
. O

In O
the O
randomized O
RCC B-Not_AE_Candidate
trial O
, O
2 O
% O
( O
5/290 O
) O
of O
patients O
receiving O
VOTRIENT O
experienced O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
or O
ischemia O
, O
0.3 O
% O
( O
1/290 O
) O
had O
a O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
and O
1 O
% O
( O
4/290 O
) O
had O
an O
event O
of O
transient B-OSE_Labeled_AE
ischemic I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
. O

In O
the O
randomized O
STS B-Not_AE_Candidate
trial O
, O
2 O
% O
( O
4/240 O
) O
of O
patients O
receiving O
VOTRIENT O
experienced O
a O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
or O
ischemia B-OSE_Labeled_AE
, O
0.4 O
% O
( O
1/240 O
) O
had O
a O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
and O
there O
were O
no O
incidents O
of O
transient B-NonOSE_AE
ischemic I-NonOSE_AE
attack I-NonOSE_AE
. O

No O
arterial B-NonOSE_AE
thromboembolic I-NonOSE_AE
events I-NonOSE_AE
were O
reported O
in O
patients O
who O
received O
placebo O
in O
either O
trial O
. O

VOTRIENT O
should O
be O
used O
with O
caution O
in O
patients O
who O
are O
at O
increased O
risk O
for O
these O
events O
or O
who O
have O
had O
a O
history O
of O
these O
events O
. O

VOTRIENT O
has O
not O
been O
studied O
in O
patients O
who O
have O
had O
an O
arterial B-Not_AE_Candidate
thromboembolic I-Not_AE_Candidate
event I-Not_AE_Candidate
within O
the O
previous O
6 O
months O
and O
should O
not O
be O
used O
in O
those O
patients O
. O

5.6 O
Venous O
Thromboembolic O
Events O
In O
RCC B-Not_AE_Candidate
and O
STS B-Not_AE_Candidate
trials O
of O
VOTRIENT O
, O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( O
VTE O
) O
including O
venous B-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
fatal O
pulmonary B-OSE_Labeled_AE
embolus I-OSE_Labeled_AE
( O
PE O
) O
have O
occurred O
. O

In O
the O
randomized O
STS B-Not_AE_Candidate
trial O
, O
venous B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
5 O
% O
of O
patients O
treated O
with O
VOTRIENT O
compared O
with O
2 O
% O
with O
placebo O
. O

In O
the O
randomized O
RCC B-Not_AE_Candidate
trial O
, O
the O
rate O
was O
1 O
% O
in O
both O
arms O
. O

Fatal B-NonOSE_AE
pulmonary B-OSE_Labeled_AE
embolus I-OSE_Labeled_AE
occurred O
in O
1 O
% O
( O
2/240 O
) O
of O
STS B-Not_AE_Candidate
patients O
receiving O
VOTRIENT O
and O
in O
no O
patients O
receiving O
placebo O
. O

There O
were O
no O
fatal O
pulmonary B-NonOSE_AE
emboli I-NonOSE_AE
in O
the O
RCC B-Not_AE_Candidate
trial O
. O

Monitor O
for O
signs O
and O
symptoms O
of O
VTE B-NonOSE_AE
and O
PE B-NonOSE_AE
. O

5.7 O
Thrombotic O
Microangiopathy O
Thrombotic B-OSE_Labeled_AE
microangiopathy I-OSE_Labeled_AE
( O
TMA O
) O
, O
including O
thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
( O
TTP O
) O
and O
hemolytic B-OSE_Labeled_AE
uremic I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
HUS O
) O
, O
has O
been O
reported O
in O
clinical O
trials O
of O
VOTRIENT O
as O
monotherapy O
, O
in O
combination O
with O
bevacizumab O
, O
and O
in O
combination O
with O
topotecan O
. O

VOTRIENT O
is O
not O
indicated O
for O
use O
in O
combination O
with O
other O
agents O
. O

Six O
of O
the O
7 O
TMA B-OSE_Labeled_AE
cases O
occurred O
within O
90 O
days O
of O
the O
initiation O
of O
VOTRIENT O
. O

Improvement O
of O
TMA B-NonOSE_AE
was O
observed O
after O
treatment O
was O
discontinued O
. O

Monitor O
for O
signs O
and O
symptoms O
of O
TMA B-NonOSE_AE
. O

Permanently O
discontinue O
VOTRIENT O
in O
patients O
developing O
TMA B-NonOSE_AE
. O

Manage O
as O
clinically O
indicated O
. O

5.8 O
Gastrointestinal O
Perforation O
and O
Fistula O
In O
the O
RCC B-Not_AE_Candidate
and O
STS B-Not_AE_Candidate
trials O
, O
gastrointestinal B-NonOSE_AE
perforation O
or O
fistula O
occurred O
in O
0.9 O
% O
( O
5/586 O
) O
of O
patients O
and O
1 O
% O
( O
4/382 O
) O
of O
patients O
receiving O
VOTRIENT O
, O
respectively O
. O

Fatal O
perfora O
tions B-NonOSE_AE
 I-NonOSE_AE
occurred O
in O
0.3 O
% O
( O
2/586 O
) O
of O
these O
patients O
in O
the O
RCC B-Not_AE_Candidate
trials O
and O
in O
0.3 O
% O
( O
1/382 O
) O
of O
these O
patients O
in O
the O
STS B-Not_AE_Candidate
trials O
. O

Monitor O
for O
signs O
and O
symptoms O
of O
gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
or O
fistula O
. O

5.9 O
Interstitial B-OSE_Labeled_AE
Lung I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ILD I-OSE_Labeled_AE
) O
/Pneumonitis O
ILD B-OSE_Labeled_AE
/ O
pneumonitis B-OSE_Labeled_AE
, O
which O
can O
be O
fatal B-NonOSE_AE
, O
has O
been O
reported O
in O
association O
with O
VOTRIENT O
. O

In O
clinical O
trials O
, O
ILD B-OSE_Labeled_AE
/ O
pneumonitis B-OSE_Labeled_AE
occurred O
in O
0.1 O
% O
of O
patients O
treated O
with O
VOTRIENT O
. O

Monitor O
patients O
for O
pulmonary O
symptoms O
indicative O
of O
ILD B-NonOSE_AE
/ O
pneumonitis B-NonOSE_AE
and O
discontinue O
VOTRIENT O
in O
patients O
developing O
ILD B-NonOSE_AE
or O
pneumonitis B-NonOSE_AE
. O

5.10 O
Reversible O
Posterior O
Leukoencephalopathy O
Syndrome O
Reversible B-OSE_Labeled_AE
Posterior I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( O
RPLS O
) O
has O
been O
reported O
in O
patients O
receiving O
VOTRIENT O
and O
may O
be O
fatal B-NonOSE_AE
. O

RPLS B-NonOSE_AE
is O
a O
neurological B-NonOSE_AE
disorder I-NonOSE_AE
which O
can O
present O
with O
headache B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
blindness B-NonOSE_AE
, O
and O
other O
visual B-NonOSE_AE
and O
neurologic O
disturbances I-NonOSE_AE
. O

Mild O
to O
severe O
hypertension B-NonOSE_AE
may O
be O
present O
. O

The O
diagnosis O
of O
RPLS B-NonOSE_AE
is O
optimally O
confirmed O
by O
magnetic O
resonance O
imaging O
. O

Permanently O
discontinue O
VOTRIENT O
in O
patients O
developing O
RPLS B-NonOSE_AE
. O

5.11 O
Hypertension O
In O
clinical O
trials O
, O
hypertension B-OSE_Labeled_AE
( O
systolic B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
or O
diastolic B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
Hg I-OSE_Labeled_AE
) O
and O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
were O
observed O
in O
patients O
treated O
with O
VOTRIENT O
. O

Blood O
pressure O
should O
be O
well O
controlled O
prior O
to O
initiating O
VOTRIENT O
. O

Hypertension B-OSE_Labeled_AE
occurs O
early O
in O
the O
course O
of O
treatment O
( O
40 O
% O
of O
cases O
occurred O
by O
Day O
9 O
and O
90 O
% O
of O
cases O
occurred O
in O
the O
first O
18 O
weeks O
) O
. O

Blood O
pressure O
should O
be O
monitored O
early O
after O
starting O
treatment O
( O
no O
longer O
than O
one O
week O
) O
and O
frequently O
thereafter O
to O
ensure O
blood O
pressure O
control O
. O

Approximately O
40 O
% O
of O
patients O
who O
received O
VOTRIENT O
experienced O
hypertension B-OSE_Labeled_AE
. O

Grade O
3 O
hypertension B-OSE_Labeled_AE
was O
reported O
in O
4 O
% O
to O
7 O
% O
of O
patients O
receiving O
VOTRIENT O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Increased B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
should O
be O
treated O
promptly O
with O
standard O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
therapy I-NonOSE_AE
and O
dose O
reduction O
or O
interruption O
of O
VOTRIENT O
as O
clinically O
warranted O
. O

VOTRIENT O
should O
be O
discontinued O
if O
there O
is O
evidence O
of O
hypertensive B-NonOSE_AE
crisis I-NonOSE_AE
or O
if O
hypertension B-NonOSE_AE
is O
severe O
and O
persistent O
despite O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
therapy I-NonOSE_AE
and O
dose O
reduction O
. O

Approximately O
1 O
% O
of O
patients O
required O
permanent O
discontinuation O
of O
VOTRIENT O
because O
of O
hypertension B-OSE_Labeled_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.12 O
Wound O
Healing O
No O
formal O
trials O
on O
the O
effect O
of O
VOTRIENT O
on O
wound B-NonOSE_AE
healing I-NonOSE_AE
have O
been O
conducted O
. O

Since O
vascular O
endothelial O
growth O
factor O
receptor O
( O
VEGFR O
) O
inhibitors O
such O
as O
pazopanib O
may O
impair B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
, O
treatment O
with O
VOTRIENT O
should O
be O
stopped O
at O
least O
7 O
days O
prior O
to O
scheduled O
surgery O
. O

The O
decision O
to O
resume O
VOTRIENT O
after O
surgery O
should O
be O
based O
on O
clinical O
judgment O
of O
adequate O
wound O
healing O
. O

VOTRIENT O
should O
be O
discontinued O
in O
patients O
with O
wound B-NonOSE_AE
dehiscence I-NonOSE_AE
. O

5.13 O
Hypothyroidism O
Hypothyroidism B-OSE_Labeled_AE
, O
confirmed O
based O
on O
a O
simultaneous O
rise B-OSE_Labeled_AE
of I-OSE_Labeled_AE
TSH I-OSE_Labeled_AE
and O
decline B-OSE_Labeled_AE
of I-OSE_Labeled_AE
T I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
, O
was O
reported O
in O
7 O
% O
( O
19/290 O
) O
of O
patients O
treated O
with O
VOTRIENT O
in O
the O
randomized O
RCC B-Not_AE_Candidate
trial O
and O
in O
5 O
% O
( O
11/240 O
) O
of O
patients O
treated O
with O
VOTRIENT O
in O
the O
randomized O
STS B-Not_AE_Candidate
trial O
. O

No O
patients O
on O
the O
placebo O
arm O
of O
either O
trial O
had O
hypothyroidism B-NonOSE_AE
. O

In O
RCC B-Not_AE_Candidate
and O
STS B-Not_AE_Candidate
trials O
of O
VOTRIENT O
, O
hypothyroidism B-OSE_Labeled_AE
was O
reported O
as O
an O
adverse O
reaction O
in O
4 O
% O
( O
26/586 O
) O
and O
5 O
% O
( O
20/382 O
) O
of O
patients O
, O
respectively O
. O

Proactive O
monitoring O
of O
thyroid O
function O
tests O
is O
recommended O
. O

5.14 O
Proteinuria O
In O
the O
randomized O
RCC B-Not_AE_Candidate
trial O
, O
proteinuria B-OSE_Labeled_AE
was O
reported O
as O
an O
adverse O
reaction O
in O
9 O
% O
( O
27/290 O
) O
of O
patients O
receiving O
VOTRIENT O
and O
in O
no O
patients O
receiving O
placebo O
. O

In O
2 O
patients O
, O
proteinuria B-OSE_Labeled_AE
led O
to O
discontinuation O
of O
treatment O
with O
VOTRIENT O
. O

In O
the O
randomized O
STS B-Not_AE_Candidate
trial O
, O
proteinuria B-OSE_Labeled_AE
was O
reported O
as O
an O
adverse O
reaction O
in O
1 O
% O
( O
2/240 O
) O
of O
patients O
, O
and O
nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
was O
reported O
in O
1 O
patient O
treated O
with O
VOTRIENT O
compared O
with O
none O
in O
patients O
receiving O
placebo O
. O

Treatment O
was O
withdrawn O
in O
the O
patient O
with O
nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

Baseline O
and O
periodic O
urinalysis O
during O
treatment O
is O
recommended O
with O
follow O
up O
measurement O
of O
24-hour O
urine O
protein O
as O
clinically O
indicated O
. O

Interrupt O
VOTRIENT O
and O
dose O
reduce O
for O
24-hour O
urine O
protein O
> O
=3 O
grams O
; O
discontinue O
VOTRIENT O
for O
repeat O
episodes O
despite O
dose O
reductions O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.15 O
Infection O
Serious O
infections B-OSE_Labeled_AE
( O
with O
or O
without O
neutropenia O
) O
, O
including O
some O
with O
fatal O
outcome O
, O
have O
been O
reported O
. O

Monitor O
patients O
for O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
. O

Institute O
appropriate O
anti-infective O
therapy O
promptly O
and O
consider O
interruption O
or O
discontinuation O
of O
VOTRIENT O
for O
serious O
infections B-NonOSE_AE
. O

5.16 O
Increased O
Toxicity O
with O
Other O
Cancer O
Therapy O
VOTRIENT O
is O
not O
indicated O
for O
use O
in O
combination O
with O
other O
agents O
. O

Clinical O
trials O
of O
VOTRIENT O
in O
combination O
with O
pemetrexed O
and O
lapatinib O
were O
terminated O
early O
due O
to O
concerns O
over O
increased O
toxicity O
and O
mortality B-NonOSE_AE
. O

The O
fatal B-NonOSE_AE
toxicities O
observed O
included O
pulmonary B-NonOSE_AE
hemorrhage I-NonOSE_AE
, O
gastrointestinal B-NonOSE_AE
hemorrhage I-NonOSE_AE
, O
and O
sudden B-NonOSE_AE
death I-NonOSE_AE
. O

A O
safe O
and O
effective O
combination O
dose O
has O
not O
been O
established O
with O
these O
regimens O
. O

5.17 O
Increased O
Toxicity O
in O
Developing O
Organs O
The O
safety O
and O
effectiveness O
of O
VOTRIENT O
in O
pediatric O
patients O
have O
not O
been O
established O
. O

VOTRIENT O
is O
not O
indicated O
for O
use O
in O
pediatric O
patients O
. O

Based O
on O
its O
mechanism O
of O
action O
, O
pazopanib O
may O
have O
severe O
effects B-OSE_Labeled_AE
on I-OSE_Labeled_AE
organ I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
and I-OSE_Labeled_AE
maturation I-OSE_Labeled_AE
during O
early O
post-natal O
development O
. O

Administration O
of O
pazopanib O
to O
juvenile O
rats O
less O
than O
21 O
days O
old O
resulted O
in O
toxicity B-NonOSE_AE
to I-NonOSE_AE
the I-NonOSE_AE
lungs I-NonOSE_AE
, O
liver O
, O
heart O
, O
and O
kidney O
and O
in O
death B-NonOSE_AE
at O
doses O
significantly O
lower O
than O
the O
clinically O
recommended O
dose O
or O
doses O
tolerated O
in O
older O
animals O
. O

VOTRIENT O
may O
potentially O
cause O
serious O
adverse B-OSE_Labeled_AE
effects I-OSE_Labeled_AE
on I-OSE_Labeled_AE
organ I-OSE_Labeled_AE
development I-OSE_Labeled_AE
in O
pediatric O
patients O
, O
particularly O
in O
patients O
younger O
than O
2 O
years O
of O
age O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.4 O
) O
] O
. O

5.18 O
Pregnancy O
VOTRIENT O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

Based O
on O
its O
mechanism O
of O
action O
, O
VOTRIENT O
is O
expected O
to O
result O
in O
adverse B-OSE_Labeled_AE
reproductive I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
. O

In O
pre-clinical O
studies O
in O
rats O
and O
rabbits O
, O
pazopanib O
was O
teratogenic B-NonOSE_AE
, O
embryotoxic B-NonOSE_AE
, O
fetotoxic B-NonOSE_AE
, O
and O
abortifacient B-NonOSE_AE
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
of O
VOTRIENT O
in O
pregnant B-Not_AE_Candidate
women O
. O

If O
this O
drug O
is O
used O
during O
pregnancy B-Not_AE_Candidate
, O
or O
if O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
taking O
this O
drug O
, O
the O
patient O
should O
be O
apprised O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Women O
of O
childbearing O
potential O
should O
be O
advised O
to O
avoid O
becoming O
pregnant B-NonOSE_AE
while O
taking O
VOTRIENT O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

